Vertex [VRTX] vs Insmed [INSM] Detailed Stock Comparison
Vertex
NASDAQ
Loading...
Insmed
NASDAQ
Loading...
TLDR: Quick Comparison Summary
Based on 19 vital metrics comparison: Vertex wins in 14 metrics, Insmed wins in 4 metrics, with 0 ties. Vertex appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Vertex | Insmed | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 27.47 | -25.76 | Insmed |
| Price-to-Book Ratio | 5.90 | 23.93 | Vertex |
| Debt-to-Equity Ratio | 8.89 | 59.14 | Vertex |
| PEG Ratio | -0.21 | 2.08 | Vertex |
| EV/EBITDA | 20.10 | -31.42 | Insmed |
| Profit Margin (TTM) | 31.86% | -259.82% | Vertex |
| Operating Margin (TTM) | 38.93% | -236.35% | Vertex |
| EBITDA Margin (TTM) | 38.93% | N/A | N/A |
| Return on Equity | 22.77% | -160.54% | Vertex |
| Return on Assets (TTM) | 13.09% | -27.03% | Vertex |
| Free Cash Flow (TTM) | $-978.00M | $-705.81M | Insmed |
| 1-Year Return | -10.20% | 111.43% | Insmed |
| Price-to-Sales Ratio (TTM) | 8.88 | 75.21 | Vertex |
| Enterprise Value | $96.50B | $28.82B | Vertex |
| EV/Revenue Ratio | 8.45 | 72.40 | Vertex |
| Gross Profit Margin (TTM) | 86.25% | 73.86% | Vertex |
| Revenue per Share (TTM) | $44 | $2 | Vertex |
| Earnings per Share (Diluted) | $14.39 | $-5.86 | Vertex |
| Beta (Stock Volatility) | 0.44 | 0.97 | Vertex |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
Vertex vs Insmed Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Vertex | 1.15% | 7.07% | 1.96% | -10.54% | -15.44% | 0.76% |
| Insmed | 3.75% | 12.69% | 5.16% | 55.54% | 108.06% | 118.44% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Vertex | -10.20% | 38.49% | 51.45% | 271.68% | 1,057.89% | 1,798.98% |
| Insmed | 111.43% | 591.72% | 323.86% | 776.65% | 2,082.86% | 1,142.28% |
News Based Sentiment: Vertex vs Insmed
Vertex
News based Sentiment: POSITIVE
Vertex Pharmaceuticals delivered strong financial results in Q2 2025 and raised its full-year guidance, coupled with positive developments in its pipeline and favorable analyst coverage. This combination of factors indicates a positive trajectory for the company and strengthens the investment case.
Insmed
News based Sentiment: MIXED
September presented a mixed bag for Insmed, with promising clinical data on the horizon and strong institutional support offset by continued profitability concerns and some bearish signals. The upcoming ERS Congress presentations are a key catalyst, but the company's financial performance remains a critical factor for investors.
Performance & Financial Health Analysis: Vertex vs Insmed
| Metric | VRTX | INSM |
|---|---|---|
| Market Information | ||
| Market Cap | $100.41B | $29.94B |
| Market Cap Category | Large cap | Large cap |
| 10 Day Avg. Volume | 2,025,380 | 2,272,080 |
| 90 Day Avg. Volume | 1,632,117 | 2,241,003 |
| Last Close | $408.85 | $152.80 |
| 52 Week Range | $362.50 - $519.88 | $60.40 - $152.85 |
| % from 52W High | -21.36% | -0.03% |
| All-Time High | $519.88 (Nov 04, 2024) | $199.38 (Aug 28, 2000) |
| % from All-Time High | -21.36% | -23.36% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.12% | 0.19% |
| Quarterly Earnings Growth | 0.12% | 0.19% |
| Financial Health | ||
| Profit Margin (TTM) | 0.32% | -2.60% |
| Operating Margin (TTM) | 0.39% | -2.36% |
| Return on Equity (TTM) | 0.23% | -1.61% |
| Debt to Equity (MRQ) | 8.89 | 59.14 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $67.02 | $5.92 |
| Cash per Share (MRQ) | $24.90 | $8.78 |
| Operating Cash Flow (TTM) | $3.85B | $-844,552,000 |
| Levered Free Cash Flow (TTM) | $2.91B | $-542,182,144 |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | N/A |
Valuation & Enterprise Metrics Analysis: Vertex vs Insmed
| Metric | VRTX | INSM |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 27.47 | -25.76 |
| Forward P/E | 21.06 | -33.49 |
| PEG Ratio | -0.21 | 2.08 |
| Price to Sales (TTM) | 8.88 | 75.21 |
| Price to Book (MRQ) | 5.90 | 23.93 |
| Market Capitalization | ||
| Market Capitalization | $100.41B | $29.94B |
| Enterprise Value | $96.50B | $28.82B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 8.45 | 72.40 |
| Enterprise to EBITDA | 20.10 | -31.42 |
| Risk & Other Metrics | ||
| Beta | 0.44 | 0.97 |
| Book Value per Share (MRQ) | $67.02 | $5.92 |
Financial Statements Comparison: Vertex vs Insmed
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | VRTX | INSM |
|---|---|---|
| Revenue/Sales | $2.96B | $107.42M |
| Cost of Goods Sold | $407.50M | $28.08M |
| Gross Profit | $2.56B | $79.34M |
| Research & Development | $978.40M | $177.19M |
| Operating Income (EBIT) | $1.15B | $-253.88M |
| EBITDA | $1.34B | $-251.35M |
| Pre-Tax Income | $1.28B | $-320.44M |
| Income Tax | $250.10M | $1.24M |
| Net Income (Profit) | $1.03B | $-321.69M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | VRTX | INSM |
|---|---|---|
| Cash & Equivalents | $4.67B | $403.25M |
| Total Current Assets | $10.01B | $1.40B |
| Total Current Liabilities | $3.78B | $239.23M |
| Long-Term Debt | $1.65B | $1.14B |
| Total Shareholders Equity | $16.50B | $99.16M |
| Retained Earnings | $10.25B | $-4.62B |
| Property, Plant & Equipment | $2.63B | $59.23M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | VRTX | INSM |
|---|---|---|
| Operating Cash Flow | $404.90M | $-175.33M |
| Capital Expenditures | $-40.70M | $-10.07M |
| Free Cash Flow | $778.20M | $-272.16M |
| Debt Repayment | $-1.30M | $-706,000 |
| Common Stock Repurchase | $-696.60M | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | VRTX | INSM |
|---|---|---|
| Shares Short | 4.05M | 10.58M |
| Short Ratio | 2.83 | 4.62 |
| Short % of Float | 0.02% | 0.06% |
| Average Daily Volume (10 Day) | 2,025,380 | 2,272,080 |
| Average Daily Volume (90 Day) | 1,632,117 | 2,241,003 |
| Shares Outstanding | 256.94M | 179.38M |
| Float Shares | 255.58M | 190.47M |
| % Held by Insiders | 0.00% | 0.01% |
| % Held by Institutions | 0.98% | 1.04% |
Dividend Analysis & Yield Comparison: Vertex vs Insmed
| Metric | VRTX | INSM |
|---|---|---|
| Last 12-Month Dividend | N/A | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | N/A |
| Ex-Dividend Date | N/A | N/A |